Apraxia: Increasing Prevalence of Several Kinds of Apraxia is Likely to Boost The Market Growth During The Forecast Period 2023 - 2030

Pune, India, 2022 /MRFR Press Release/- Market Research Future has a half cooked research report on the global apraxia market.

Market Highlights

There are several types of apraxia such as ideomotor apraxia, ideational/conceptual apraxia, buccofacial or orofacial apraxia, constructional apraxia, apraxia of speech, and others. Buccofacial or orofacial apraxia is the most common type, which causes the inability to carry out facial movements on commands such as whistling, coughing, or others.

However, apraxia is found in people with a migraine, especially, in women. According to Migraine Research Foundation, (2014), migraine was the 3rd most prevalent illness in the world. Nearly 1 in 4 U.S. households includes someone with a migraine. Moreover, 12% of the population including children have migraine problem. 18% of American women, 6% of men, and 10% of children experience migraines. Mostly migraine occurs at the age of 25-55, which, in turn, is projected increase the market growth.

The Apraxia Market is expected to reach USD 3.72 Billion by 2030 at 6.90% CAGR during the forecast period 2023-2030.

Increasing prevalence of neurological disorder like apraxia, epilepsy, rising need for better treatment, increasing investment in biotechnology and pharmaceutical industries in R&D, and availability of funds drive the growth of the market. Moreover, increasing government support for research & development, changing lifestyle, and rapid development in technology is projected to fuel the market growth during the forecast period. However, the high cost of the treatment may slow the market growth during the review period.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Apraxia Market Research Report

Regional Analysis

The Americas dominate the global apraxia market owing to the presence of a huge patient population with a neurological disorder such as depression, epilepsy, and migraine, high health care spending, and increasing government support for research & development.  

Europe holds the second largest share of the global market. The increasing focus of various government agencies on treating neurological disorders such as epilepsy, depression, and heart attacks may have a positive impact on the growth of the market. The growing public awareness further boosts the adoption of these devices in the European market.

Asia Pacific is the fastest growing market across the globe. Japan holds the major share of the regional market due to the availability of technology and huge healthcare spending. Rapidly developing the economy, increasing healthcare expenditure, and government initiatives for research & development may drive the market in China and India over the assessment period.  

The Middle East & Africa holds the least share of the global market due to limited availability of medical facilities. The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle East & African market. Whereas, the African region is expected to witness a moderate growth.

Segmentation

The global market has been segmented on the basis of types, diagnosis, treatment, and end user. On the basis of types, the market is segmented into ideomotor apraxia, ideational/conceptual apraxia, buccofacial or orofacial apraxia, constructional apraxia, gait apraxia, limb-kinetic apraxia, oculomotor apraxia, apraxia of speech. On the basis of the diagnosis, the market is segmented into a test to measure upper limb apraxia, MRI, and others. On the basis of treatment, the market is segmented into speech therapy, occupational therapy, physical therapy, and others. On the basis of the end user, the market is segmented into hospitals & clinics, research centers, and others. 

Key Players

Some of key the players in the market are Medtronic Plc., Codman & Shurtleff, Inc., Raumedic AG, Vittamed, Sophysa Ltd., MicroPort Scientific Corporation, Orsan Medical Technologies, and Spiegelberg GmbH, Johnson & Johnson, Sophysa Ltd, HaiWeiKang, Head Sense Medical, InfraScan, Inc., Integra Life Sciences Corporation, and others.